Keyword: Pascal Soriot

aznwilmington

With trial failure, AZ dials back $3.5B hopes for Brilinta

When Pascal Soriot took the reins at AstraZeneca in 2013, he plucked out Brilinta as a growth product. Soriot figured the struggling drug could turn around with a little TLC. And when Pfizer came calling with a buyout offer in 2014, Soriot doubled down, setting out a $3.5 billion goal for sales by 2023. Now, that project has fallen short again.